FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2922244800> ?p ?o ?g. }

• W2922244800 abstract "Breast cancer will affect one in eight women during their lifetime. The opportunity to restore the removed tissue and cosmetic appearance is provided by reconstructive breast surgery following skin-sparing mastectomy (SSM). Mastectomy skin flap necrosis (MSFN) is a common complication following SSM breast reconstruction. This postoperative complication can be prevented by intraoperative assessment of mastectomy skin flap viability and intervention when tissue perfusion is compromised. Indocyanine green fluorescence angiography is presumed to be a better predictor of MSFN compared to clinical evaluation alone.To assess the effects of indocyanine green fluorescence angiography (ICGA) for preventing mastectomy skin flap necrosis in women undergoing immediate breast reconstruction following skin-sparing mastectomy. To summarise the different ICGA protocols available for assessment of mastectomy skin flap perfusion in women undergoing immediate breast reconstructions following skin-sparing mastectomy.We searched the Cochrane Breast Cancer Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL; Issue 3, 2019), MEDLINE, Embase, the World Health Organization's International Clinical Trials Registry Platform (ICTRP) and Clinicaltrials.gov in April 2019. In addition, we searched reference lists of published studies.We included studies that compared the use of ICGA to clinical evaluation to assess mastectomy skin vascularisation and recruited women undergoing immediate autologous or prosthetic reconstructive surgery following SSM for confirmed breast malignancy or high risk of developing breast cancer.Two review authors independently assessed the risk of bias of the included nonrandomised studies and extracted data on postoperative outcomes, including postoperative MSFN, reoperation, autologous flap necrosis, dehiscence, infection, haematoma and seroma, and patient-related outcomes. The quality of the evidence was assessed using the GRADE approach and we constructed two 'Summary of finding's tables: one for the comparison of ICGA to clinical evaluation on a per patient basis and one on a per breast basis.Nine nonrandomised cohort studies met the inclusion criteria and involved a total of 1589 women with 2199 breast reconstructions. We included seven retrospective and two prospective cohort studies. Six studies reported the number of MSFN on a per breast basis for a total of 1435 breasts and three studies reported the number of MSFN on a per patient basis for a total of 573 women. Five studies reported the number of other complications on a per breast basis for a total of 1370 breasts and four studies reported the number on a per patient basis for a total of 613 patients. Therefore, we decided to pool data separately. Risk of bias for each included nonrandomised study was assessed using the Newcastle-Ottawa Scale for cohort studies. There was serious concern with risk of bias due to the nonrandomised study design of all included studies and the low comparability of cohorts in most studies. The quality of the evidence was found to be very low, after downgrading the quality of evidence twice for imprecision based on the small sample sizes and low number of events in the included studies. Postoperative complications on a per patient basis We are uncertain about the effect of ICGA on MSFN (RR 0.79, 95% CI 0.40 to 1.56; three studies, 573 participants: very low quality of evidence), infection rates (RR 0.91, 95% CI 0.60 to 1.40; four studies, 613 participants: very low quality of evidence), haematoma rates (RR 0.87, 95% CI 0.30 to 2.53; two studies, 459 participants: very low quality of evidence) and seroma rates (RR 1.68, 95% CI 0.41 to 6.80; two studies, 408 participants: very low quality of evidence) compared to the clinical group. We found evidence that ICGA may reduce reoperation rates (RR 0.50, 95% CI 0.35 to 0.72; four studies, 613 participants: very low quality of evidence). One study considered dehiscence as an outcome. In this single study, dehiscence was observed in 2.2% of participants (4/184) in the ICGA group compared to 0.5% of participants (1/184) in the clinical group (P = 0.372). The RR was 4.00 (95% CI 0.45 to 35.45; one study; 368 participants; very low quality of evidence). Postoperative complications on a per breast basis We found evidence that ICGA may reduce MSFN (RR 0.62, 95% CI 0.48 to 0.82; six studies, 1435 breasts: very low quality of evidence), may reduce reoperation rates (RR 0.65, 95% CI 0.47 to 0.92; five studies, 1370 breasts: very low quality of evidence) and may reduce infection rates (RR 0.65, 95% CI 0.44 to 0.97; five studies, 1370 breasts: very low quality of evidence) compared to the clinical group. We are uncertain about the effect of ICGA on haematoma rates (RR 1.53, CI 95% 0.47 to 4.95; four studies, 1042 breasts: very low quality of evidence) and seroma rates (RR 0.71, 95% CI 0.37 to 1.35; two studies, 528 breasts: very low quality of evidence). None of the studies reported patient-related outcomes. ICGA protocols: eight studies used the SPY System and one study used the Photodynamic Eye imaging system (PDE) to assess MSFN. ICGA protocols in the included studies were not extensively described in most studies.Although mastectomy skin flap perfusion is performed more frequently using ICGA as a helpful tool, there is a lack of high-quality evidence in the context of randomised controlled trials. The quality of evidence in this review is very low, since only nonrandomised cohort studies have been included. With the results from this review, no conclusions can be drawn about what method of assessment is best to use during breast reconstructive surgery. High-quality randomised controlled studies that compare the use of ICGA to assess MSFN compared to clinical evaluation are needed." @default.
• W2922244800 created "2019-03-22" @default.
• W2922244800 creator A5002436134 @default.
• W2922244800 creator A5005096173 @default.
• W2922244800 creator A5067446605 @default.
• W2922244800 creator A5082362428 @default.
• W2922244800 creator A5087173002 @default.
• W2922244800 date "2020-04-22" @default.
• W2922244800 modified "2023-10-05" @default.
• W2922244800 title "Indocyanine green angiography for preventing postoperative mastectomy skin flap necrosis in immediate breast reconstruction" @default.
• W2922244800 cites W1757407923 @default.
• W2922244800 cites W1987002537 @default.
• W2922244800 cites W2013336279 @default.
• W2922244800 cites W2014493386 @default.
• W2922244800 cites W2023900647 @default.
• W2922244800 cites W2039675683 @default.
• W2922244800 cites W2041572042 @default.
• W2922244800 cites W2052975420 @default.
• W2922244800 cites W2072733010 @default.
• W2922244800 cites W2091386904 @default.
• W2922244800 cites W2109210596 @default.
• W2922244800 cites W2109887283 @default.
• W2922244800 cites W2117007317 @default.
• W2922244800 cites W2122359067 @default.
• W2922244800 cites W2128458647 @default.
• W2922244800 cites W2141063128 @default.
• W2922244800 cites W2156098321 @default.
• W2922244800 cites W2275281441 @default.
• W2922244800 cites W2336600677 @default.
• W2922244800 cites W2468996569 @default.
• W2922244800 cites W2469890028 @default.
• W2922244800 cites W2474126885 @default.
• W2922244800 cites W2503780859 @default.
• W2922244800 cites W2589491659 @default.
• W2922244800 cites W2594961765 @default.
• W2922244800 cites W2607307465 @default.
• W2922244800 cites W2750665258 @default.
• W2922244800 cites W2763895804 @default.
• W2922244800 cites W2766993364 @default.
• W2922244800 cites W2789992956 @default.
• W2922244800 cites W2790470170 @default.
• W2922244800 cites W2792978025 @default.
• W2922244800 cites W2801440380 @default.
• W2922244800 cites W2804893169 @default.
• W2922244800 cites W2805177050 @default.
• W2922244800 cites W2806507299 @default.
• W2922244800 cites W2883532013 @default.
• W2922244800 cites W2889646458 @default.
• W2922244800 cites W2889936038 @default.
• W2922244800 cites W2910708586 @default.
• W2922244800 cites W2940694080 @default.
• W2922244800 cites W2964839589 @default.
• W2922244800 cites W4250419464 @default.
• W2922244800 cites W4252714226 @default.
• W2922244800 cites W90733986 @default.
• W2922244800 doi "https://doi.org/10.1002/14651858.cd013280.pub2" @default.
• W2922244800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7175780" @default.
• W2922244800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32320056" @default.
• W2922244800 hasPublicationYear "2020" @default.
• W2922244800 type Work @default.
• W2922244800 sameAs 2922244800 @default.
• W2922244800 citedByCount "22" @default.
• W2922244800 countsByYear W29222448002020 @default.
• W2922244800 countsByYear W29222448002021 @default.
• W2922244800 countsByYear W29222448002022 @default.
• W2922244800 countsByYear W29222448002023 @default.
• W2922244800 crossrefType "journal-article" @default.
• W2922244800 hasAuthorship W2922244800A5002436134 @default.
• W2922244800 hasAuthorship W2922244800A5005096173 @default.
• W2922244800 hasAuthorship W2922244800A5067446605 @default.
• W2922244800 hasAuthorship W2922244800A5082362428 @default.
• W2922244800 hasAuthorship W2922244800A5087173002 @default.
• W2922244800 hasBestOaLocation W29222448002 @default.
• W2922244800 hasConcept C121608353 @default.
• W2922244800 hasConcept C126322002 @default.
• W2922244800 hasConcept C139812875 @default.
• W2922244800 hasConcept C141071460 @default.
• W2922244800 hasConcept C142724271 @default.
• W2922244800 hasConcept C2777757722 @default.
• W2922244800 hasConcept C2779409168 @default.
• W2922244800 hasConcept C2781001896 @default.
• W2922244800 hasConcept C2781065829 @default.
• W2922244800 hasConcept C530470458 @default.
• W2922244800 hasConcept C535046627 @default.
• W2922244800 hasConcept C71924100 @default.
• W2922244800 hasConcept C81182388 @default.
• W2922244800 hasConceptScore W2922244800C121608353 @default.
• W2922244800 hasConceptScore W2922244800C126322002 @default.
• W2922244800 hasConceptScore W2922244800C139812875 @default.
• W2922244800 hasConceptScore W2922244800C141071460 @default.
• W2922244800 hasConceptScore W2922244800C142724271 @default.
• W2922244800 hasConceptScore W2922244800C2777757722 @default.
• W2922244800 hasConceptScore W2922244800C2779409168 @default.
• W2922244800 hasConceptScore W2922244800C2781001896 @default.
• W2922244800 hasConceptScore W2922244800C2781065829 @default.
• W2922244800 hasConceptScore W2922244800C530470458 @default.
• W2922244800 hasConceptScore W2922244800C535046627 @default.
• W2922244800 hasConceptScore W2922244800C71924100 @default.
• W2922244800 hasConceptScore W2922244800C81182388 @default.
• W2922244800 hasIssue "4" @default.

• next